With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm... Show more
Kimberly-Clark occupies a defensive niche within consumer staples, anchored by category-leading brands such as Huggies, Kleenex, Cottonelle, Scott, Kotex, and Depend. Its market positioning rests on essential, repeat-purchase categories that historically generate resilient demand through economic cycles. North America represents a little over half of sales, with meaningful exposure across Europe, Asia, and Latin America, while a professional segment broadens reach into workplace and healthcare settings.
The medium-term story is shifting from a pure hygiene-and-tissue operator toward a diversified household and personal-health platform. The planned Kenvue acquisition would bring brands including Tylenol, Band-Aid, Neutrogena, and Listerine into the fold, adding categories with different margin profiles and stronger historical pricing power than commodity-linked paper goods. Management has cited a strategy of reorienting toward higher-growth Personal Care and North America while advancing an alternative natural-fiber program in tissue that could reduce forest-fiber exposure over time.
The structural risks are equally visible. Elevated leverage, estimated near 3.9 times debt-to-equity by some analysts, limits flexibility as the company finances a large transaction. Divestitures required by European regulators—notably the tampon and feminine-hygiene brands—trim regional scope but are commercially narrow. Execution on the merger remains the central question for investors assessing future outlook.
Several developments could reshape sentiment over the coming quarters. First, the completion and integration of the Kenvue transaction is the dominant catalyst; management has pointed to cost and revenue synergies through 2029, but financing up to roughly $7 billion in new notes raises interest expense and concentrates attention on deleveraging progress.
Second, the China diaper recovery timeline matters. The social-commerce disruption shifted product discovery toward short-video and livestream channels, and a slower-than-expected rebound could keep organic growth below category averages.
Third, innovation rollout offers upside. Management has described a personal-care pipeline over the next three years it considers stronger than the prior decade, alongside additional tissue innovations and the alternative-fiber initiative now progressing toward a pilot facility.
Analyst ratings and price targets remain in flux. Piper Sandler recently raised its target to $137 while maintaining a Buy, RBC Capital reiterated a Buy with a $162 target, and Deutsche Bank and UBS lifted targets to $115 and $119 respectively with Hold ratings. Conversely, Wells Fargo holds an Equal Weight at $110, and TD Cowen has trimmed its target, citing a "challenging" 2026. Consensus averages cluster in the low-to-mid $110s across major aggregators, with a wide high-to-low dispersion that underscores genuine disagreement about the merger's value creation.
Kimberly-Clark's trajectory is tightly linked to commodity inputs, particularly pulp and oil-derived materials. Elevated energy prices feed directly into manufacturing, freight, and logistics costs, compressing margins unless offset by pricing or productivity. The company has historically used price increases and productivity programs—management cited industry-leading productivity near 6.4%—to defend profitability, but promotional intensity in categories such as diapers can constrain pricing power.
Interest rates represent a second macro lever. A debt-financed acquisition becomes more expensive in a higher-rate environment, raising the opportunity cost of capital and pressuring earnings available for dividends and buybacks. Consumer demand cycles matter less for staples than for discretionary goods, yet softer North American category growth and retailer destocking have already pressured shipment volumes.
Finally, the regulatory climate shapes the deal's final structure. Conditional European clearance signals progress but imposes divestitures, and ongoing scrutiny of consumer-health combinations could affect the pace and cost of integration across markets.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors monitoring Kimberly-Clark's evolving outlook, the Trend Prediction Engine offers a data-driven complement to fundamental research.
For 2026, Kimberly-Clark's guidance points to organic sales growth trailing its categories' roughly 2% weighted average, with adjusted earnings per share (EPS) expected to decline by a low single-digit percentage. Consensus revenue forecasts have been revised modestly higher alongside the Kenvue combination, while EPS estimates have come down, reflecting both the China disruption and integration costs. The next several quarters will test whether the company can stabilize volume and convert innovation into sustained unit growth.
Looking beyond 2026, the long-term investment case hinges on a few structural themes. Portfolio diversification into consumer health could reduce sensitivity to pulp-price cycles and expand addressable markets. Margin sustainability depends on productivity gains and input-cost management, particularly if oil-related inflation persists into 2027. Capital allocation will be defined by deleveraging, dividend continuity, and selective buybacks, with rating agencies and shareholders closely watching leverage relative to earnings.
Competitive threats include agile digital-native rivals in China, private-label encroachment in North America, and intensifying promotional activity. On the positive side, a defensible brand portfolio, geographic diversification, and a strong innovation roadmap provide a foundation for gradual improvement. Analyst expectations remain divided: some firms see merger-driven upside, while others view execution risk and muted category growth as constraints. The coming year will clarify whether Kimberly-Clark's transformation strengthens its market positioning or merely adds complexity.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, KMB has been loosely correlated with UL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if KMB jumps, then UL could also see price increases.
| Ticker / NAME | Correlation To KMB | 1D Price Change % | ||
|---|---|---|---|---|
| KMB | 100% | +1.07% | ||
| UL - KMB | 59% Loosely correlated | +0.73% | ||
| IPAR - KMB | 53% Loosely correlated | +3.37% | ||
| CHD - KMB | 50% Loosely correlated | +1.06% | ||
| KVUE - KMB | 42% Loosely correlated | N/A | ||
| EPC - KMB | 42% Loosely correlated | +3.34% | ||
More | ||||
a company, which engages in the manufacturing of paper based products and providing cleaning solutions
Industry HouseholdPersonalCare
The 10-day RSI Oscillator for KMB moved out of overbought territory on October 26, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In 19 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at 61%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KMB as a result. In 45 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 49%.
The Moving Average Convergence Divergence Histogram (MACD) for KMB turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 20 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 45%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
KMB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
KMB moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KMB crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 38%.
Following a +3.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where KMB advanced for three days, in 130 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 42%.
The Aroon Indicator entered an Uptrend today. In 84 of 191 cases where KMB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. KMB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.607) is normal, around the industry mean (21.731). P/E Ratio (18.409) is within average values for comparable stocks, (16.288). Projected Growth (PEG Ratio) (2.018) is also within normal values, averaging (1.518). Dividend Yield (0.047) settles around the average of (0.032) among similar stocks. P/S Ratio (1.971) is also within normal values, averaging (1.902).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.